Core Insights - The article discusses the 15 most promising stocks under $100 to buy, highlighting their potential for growth and recent developments that may impact investor sentiment. Group 1: GeneDx Holdings Corp. (NASDAQ:WGS) - GeneDx Holdings Corp. has partnered with Zevra Therapeutics to launch a genetic testing program for Niemann-Pick disease type C, aiming to expand access to its ExomeDx test for patients in the US [7][8]. - The program seeks to provide high-quality exome sequencing at no charge to eligible patients, facilitating quicker diagnoses and informed clinical decision-making [7][8]. - De-identified data from the testing will be integrated into GeneDx Infinity, enhancing understanding of disease biology and accelerating the journey from diagnosis to treatment [9]. Group 2: Booz Allen Hamilton Holding Corporation (NYSE:BAH) - Booz Allen Hamilton announced an investment in Hadean, a UK-based tech firm specializing in AI-powered digital wargaming, marking its first international investment [11]. - This collaboration aims to modernize military training and mission rehearsals for the US and its allies through advanced synthetic environments [12]. - The technologies developed are intended to replace legacy systems with scalable and secure capabilities, with applications across defense, civil, intelligence, and national security sectors [13].

Core Insights - GeneDx Holdings (WGS) has launched a sponsored genetic testing program in collaboration with Zevra Therapeutics to enhance the diagnosis of Niemann-Pick Disease Type C (NPC), a rare inherited disorder [1][2]. Company Developments - The initiative will provide access to GeneDx's ExomeDx test at no cost for eligible U.S. patients, allowing for quicker and more accurate diagnoses, with results expected in about three weeks [7][10]. - De-identified data from the testing program will be incorporated into GeneDx Infinity, the company's rare disease dataset, to further research and expedite NPC diagnosis [2][3]. - The partnership aims to eliminate barriers to high-quality exome sequencing, thereby improving clinical decision-making for treatable conditions like NPC [3][11]. - GeneDx's market capitalization currently stands at $2.77 billion [6]. Market Context - The genetic testing market is projected to reach a value of $27.32 billion by 2026, with a compound annual growth rate (CAGR) of 11.3% through 2035, driven by factors such as the rising prevalence of chronic and genetic diseases and advancements in technology [12][13]. - The collaboration with Zevra Therapeutics may create opportunities for ongoing partnerships related to the clinical development and commercialization of rare disease therapies [5].